Petrov E A, Malabuiok D M, Zheng H, Mokrushina Yu A, Abrikosova V A, Kuzmin Yu B, Tzarapaev P V, Kochkina S O, Eltsov I V, Knorre V D, Smirnov I V, Terekhov S S, Mamedli Z, Kushlinskii N E, Rogozhin D V, Matveev V B, Kononets P V, Stilidi I S, Zhang H, Gabibov A G
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997 Russian Federation.
State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, 94 Weijin Road, Tianjin, 300071 China.
Acta Naturae. 2024 Jul-Sep;16(3):67-73. doi: 10.32607/actanaturae.27353.
Cancer is a major global health problem. The type of malignant neoplasm and the potency of the immune response against tumors are two of the key factors influencing the outcome of the disease. The degree of tumor infiltration by lymphocytes plays an important role in antitumor response development, generally correlating with a favorable prognosis of treatment for certain cancers. We analyzed the abundance of tumor-infiltrating B cells (TIBs) in solid tumors of different cancers. TIBs were shown to be more abundant in colon and sigmoid colon cancer samples compared with cecal, rectal, and kidney cancer samples. The median and interquartile range of the TIB fraction were 11.5% and 4-20% in colon cancer, 6% and 3-11% in sigmoid colon cancer, 2.7% and 0.7-3.7% in cecal cancer, 2.5% and 0.9-3.6% in rectal cancer, 1.4% and 1.0-2.3% in kidney cancer, and 3.0% and 1.8-12% in lung cancer, respectively. However, there were no significant differences in the abundance of TIBs among samples at different stages of the cancer. Hence, investigation of the B cell response in colon cancer is of particular interest, since increased quantities of TIBs may indicate the existence of immunogenic tumor markers or the cell-cell interactions involved in disease progression. We believe that studying the diversity of TIBs in colon cancer will increaseour understanding of the mechanisms of the disease, contributing to the identification of new molecular targets for targeted oncotherapy.
癌症是一个重大的全球健康问题。恶性肿瘤的类型以及针对肿瘤的免疫反应强度是影响疾病预后的两个关键因素。淋巴细胞对肿瘤的浸润程度在抗肿瘤反应的发展中起着重要作用，通常与某些癌症治疗的良好预后相关。我们分析了不同癌症实体瘤中肿瘤浸润B细胞（TIBs）的丰度。结果显示，与盲肠、直肠癌和肾癌样本相比，结肠癌和乙状结肠癌样本中的TIBs更为丰富。结肠癌中TIBs比例的中位数和四分位间距分别为11.5%和4 - 20%，乙状结肠癌为6%和3 - 11%，盲肠癌为2.7%和0.7 - 3.7%，直肠癌为2.5%和0.9 - 3.6%，肾癌为1.4%和1.0 - 2.3%，肺癌为3.0%和1.8 - 12%。然而，癌症不同阶段样本中TIBs的丰度没有显著差异。因此，对结肠癌中B细胞反应的研究特别有意义，因为TIBs数量的增加可能表明存在免疫原性肿瘤标志物或参与疾病进展的细胞间相互作用。我们相信，研究结肠癌中TIBs的多样性将增进我们对该疾病机制的理解，有助于确定靶向肿瘤治疗的新分子靶点。
